Changes in the treatment landscape of metastatic hormone‐sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter studyFumihiko Urabe, Yu Imai, Kosuke Iwatani et al.|International Journal of Urology|2024Cited by 20
Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: Real-world data from a multicenter studyFumihiko Urabe, Takahiro Kimura, Kojiro Tashiro et al.|Urologic Oncology Seminars and Original Investigations|2025Cited by 11
Real-world outcomes of adjuvant immunotherapy candidates with upper tract urothelial carcinoma: results of a multicenter cohort studyHirokazu Kagawa, Fumihiko Urabe, Yuria Kiuchi et al.|International Journal of Clinical Oncology|2023Cited by 10
Clinical significance of PSA dynamics in castration-sensitive prostate cancer treated with ARSI doublet therapy: A multicenter studyFumihiko Urabe, Takahiro Kimura, Shingo Hatakeyama et al.|Urologic Oncology Seminars and Original Investigations|2024Cited by 7
PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone‐Sensitive Prostate Cancer (mHSPC) in Real‐World Analyses?Tatsuya Shimomura, Naoki Otsuka, Fumihiko Urabe et al.|The Prostate|2025Cited by 4